Close Menu

NEW YORK — Indivumed and Ultivue said on Wednesday that they have agreed to combine certain of their technologies into an offering for personalized cancer drug development.

Under the terms of the deal, the companies will join Indivumed's collection of standardized tissue biospecimens and immunohistochemistry (IHC) expertise with Ultivue's InSituPlex platform for high-throughput multiplex immunofluorescence.

Additional terms were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.